A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Vebreltinib (Primary)
- Indications Glioma
- Focus Adverse reactions
- Sponsors Beijing Pearl Biotechnology
- 02 Mar 2020 Status changed from recruiting to completed.
- 29 Aug 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.
- 04 Apr 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jul 2018.